Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
RTB Digital, Inc. appointed Erin Schaefer, a former Google and General Catalyst executive, to its Board of Directors effective October 1, 2026. Ms. Schaefer will receive an annual equity award of restricted stock units (RSUs) with a grant-date fair value of $150,000, along with reimbursement for business expenses.
Option Care Health Signs $5.8B M&A Deal with Investor Group
Option Care Health has entered into a definitive agreement to be acquired by an investor group led by Clayton, Dubilier & Rice (CD&R) and McKesson Corporation for $32.05 per share in cash. The transaction reflects a total enterprise value of approximately $5.8 billion and will result in Option Care Health becoming a privately held company with CD&R as the majority owner.
ONAR Holding Corporation appointed Kelly Anderson as Interim Chief Financial Officer, effective October 1, 2026, to lead the company's Nasdaq uplisting preparation and financial integration of Advertise Purple. Ms. Anderson, who previously served as the company's Audit Committee Chair, resigned from the Board of Directors to assume the role under an interim services agreement with CXO Executive Solutions.
MAIA Biotechnology, Inc. has prepared and posted a new corporate investor presentation and a summary highlighting its operations and performance to its website. Management intends to use these materials for upcoming presentations to investors and analysts starting October 6, 2026.
HubSpot reaffirmed its Q3 2026 and full-year 2026 financial guidance while announcing a restructuring plan to eliminate approximately 7% of its workforce (660 employees). The company expects to incur restructuring charges between $65 million and $75 million as it reorganizes to focus on AI-driven customer outcomes and a flatter management structure.
Stryker announced a planned leadership succession where Kevin Lobo will resign as CEO on December 31, 2026, and transition to Executive Chair of the Board. Spencer Stiles, the current President and COO, has been appointed to succeed Lobo as CEO and will join the Board of Directors effective January 1, 2027.
International Bancshares Corporation (IBC) is voluntarily withdrawing its common stock listing from Nasdaq to transfer to the newly formed Texas Stock Exchange (TXSE). The company expects to cease trading on Nasdaq on October 16, 2026, and begin trading on the TXSE under its current ticker 'IBOC' on October 19, 2026.
ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant non-small cell lung cancer did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review. While the drug showed clinical benefit in secondary endpoints and a consistent safety profile, it failed to show a statistically significant improvement over chemotherapy. The company is currently evaluating the full dataset to determine the future development path for the candidate.
PDS Biotechnology announced it will host a virtual Key Opinion Leader (KOL) event on October 15, 2026, to discuss clinical outcomes from the PDS0301 Phase 2 trials. The event will focus on the metastatic colorectal cancer (mCRC) cohort, specifically patients with unresectable microsatellite stable (MSS) liver metastases, a population where immunotherapy has historically been ineffective.
Netlist Licensing Deal with Micron Technology, Inc Worth $600M
Netlist entered into a five-year patent license and settlement agreement with Micron Technology, resolving all pending legal proceedings between the companies. Micron will pay Netlist $30 million per quarter through Q3 2031, totaling $600 million, and will also purchase 10 million shares of Netlist common stock for $1 million.
Mckesson Signs $5.8B M&A Deal with Option Care Health, Inc.
McKesson Corporation and Clayton, Dubilier & Rice (CD&R) have entered into a definitive agreement to acquire Option Care Health for $32.05 per share, representing a total enterprise value of approximately $5.8 billion. Upon closing, CD&R will hold a majority stake while McKesson will hold a minority interest in the home and alternate site infusion services provider. The deal aligns with McKesson's strategy to expand access to innovative therapies in lower-cost community and home settings.
1606 Corp. provided an operational update on its East Texas energy and data center project following a week of site visits and meetings with prospective financing groups, data center operators, and power offtakers. The company is currently evaluating multiple strategic paths for the 132-acre site, including potential joint ventures, project financing, power offtake arrangements, or an outright sale of its contractual rights. No specific transaction structure or counterparty has been selected at this time.
Lamb Weston reported Q1 fiscal 2027 net sales of $1.67 billion, up 1% year-over-year, with adjusted diluted EPS of $0.75. The company increased its full-year 2027 outlook for net sales, adjusted EBITDA, and adjusted EPS despite inflationary pressures and challenging market conditions in EMEA.
Term
Q1 2027
Earnings call
Oct 6, 2026, 9:00 AM ET
“We are off to a solid start to the year, delivering first quarter net sales and profit above our expectations. Our first quarter results were driven by continued momentum in North America where our strong customer relationships fueled sales volume growth and we continued to drive cost savings.”
Mike Smith, president and chief executive officer of Lamb Weston
“We continue to experience unexpected inflationary pressure across key input costs and freight expense. Our teams are addressing cost inflation by working with suppliers and hedging where possible. Furthermore, we have benefited from capacity optimization initiatives started over a year ago in North America, which have led to an approximate 10 percentage point increase in utilization.”
Mike Smith, president and chief executive officer of Lamb Weston
H.B. Fuller Company commenced a private offering of $950 million in senior unsecured notes due 2034 to fund its acquisition of Advanced Medical Solutions Group plc (AMS). The proceeds will also be used to repay existing debt under its credit agreement and redeem its 4.000% notes due 2027.
Portillo's Inc. announced that Jill Waite will depart as Chief People Officer effective November 1, 2026. Her departure is treated as a qualifying termination, entitling her to severance benefits including one year of base salary, a prorated 2026 bonus, and accelerated vesting of 26,077 restricted stock units.
B&G Foods Deal Termination with Nortera Foods Inc.
B&G Foods and Nortera Foods mutually terminated their agreement for the sale of the Green Giant and Le Sieur vegetable product lines in Canada after failing to obtain regulatory approval under Canada’s Competition Act by the outside date. As a result, B&G Foods will continue to own and operate the business, while Nortera will pay a $1.6 million termination fee and expense reimbursement.
Telomir Pharmaceuticals raised approximately $5.6 million in a PIPE financing through the issuance of 4,843,300 shares of common stock at $1.16 per share. The offering included a $1.0 million investment from existing shareholder John Paul DeJoria and will be used to fund the clinical development of Telomir-Zn for triple-negative breast cancer.
Value
$5.6M
Counterparty
John Paul DeJoria
“I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir. Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease. Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients.”
John Paul DeJoria
“We have been very deliberate about how and when we access the capital markets. Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders. As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead.”
SideChannel, Inc. filed a certificate of amendment to its certificate of incorporation to significantly reduce its authorized capital stock. The amendment decreased authorized common shares from 681 million to 13.1 million and authorized preferred shares from 10 million to 1 million.
Boost Run Inc.'s subsidiary entered into a material service agreement with Cohere Inc to provide dedicated GPU cloud computing infrastructure and related services. Cohere has committed to pay approximately $525.6 million over a five-year term, with infrastructure delivery expected to begin in the second quarter of 2027.
Entera Bio appointed Laura Hamill, a former executive at Gilead and Amgen, to its Board of Directors effective December 1, 2026. She replaces Yonatan Malca, who is stepping down from the Board after 16 years of service. Ms. Hamill will serve on the audit and corporate governance committees and participate in the company's standard non-employee director compensation plan.
Evolution Metals & Technologies Partnership with INERGX Energy Optimisation Ltd.
Evolution Metals & Technologies Corp. (EM&T) entered into a Strategic Partnership Letter of Intent with UK-based INERGX to engineer and service energy storage systems for EM&T's planned critical materials facility in the U.S. The partnership includes a non-China supply mandate for battery components and a 10-year anticipated service term. The facility is planned to reach up to 5 GW of on-site capacity at full build-out, powered by on-site LNG generation.
OFS Capital Divestiture to New Investor for $52.3M
OFS Capital Corporation's subsidiary, SBIC I LP, admitted a third-party investor who acquired a 56.62% limited partnership interest for $52.3 million. SBIC I LP holds a significant stake in Pfanstiehl Holdings, Inc., and the proceeds will be used by the company to fund new investments and for general corporate purposes.
Regeneron Pharmaceuticals Research Collaboration with Sanofi Worth $1B
Regeneron and Sanofi entered into a Sixth Amendment to their existing Antibody LCA to co-develop and co-commercialize four new long-acting antibodies targeting IL-13, IL-4, and IL-4Rα. Sanofi will pay Regeneron an upfront payment of $1.0 billion and up to $7.0 billion in potential development, regulatory, and commercial milestones, with global profits and development costs shared equally.
60 Degrees Pharmaceuticals updated its investor presentation and held a webinar to discuss interim data from its clinical study of tafenoquine for severe babesiosis. The presentation covers clinical context, DSMB feedback from the hospital study, and the regulatory path forward for the treatment.
Valion Bio issued a press release highlighting the appointment and strategic goals of its new Board Chair, Thomas Jensen, who joined the board in September 2026. Jensen, the current CEO of Allarity Therapeutics, will focus on advancing the company's lead candidate, Entolimod, as a medical countermeasure for acute radiation syndrome. The company is leveraging Jensen's experience in biotech turnarounds to align strategic priorities with disciplined resource allocation.
Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy demonstrated a statistically significant median progression-free survival of 17.7 months compared to 2 months for apalutamide alone (P=0.0008). Based on these results, the company has modified the trial protocol to enroll patients earlier in the disease progression and targets trial completion by Q4 2027.
Borr Drilling Insider Tor Olav Troim Buys $6.2M of Stock
Tor Olav Troim bought 1,500,000 shares of Borr Drilling Ltd at $4.13 a share, worth $6.2M in total on Oct 5, 2026. Shares held after the trade: 32,035,941 (+4.9%).
Professional Diversity Network Capacity Expansion: $1.18M Investment
Professional Diversity Network's subsidiary, PDN Intelligence, committed $1.177 million to acquire and finance two NVIDIA B300 GPU systems, marking its initial entry into AI computing infrastructure. The company is leasing one system to Goodwill Labs and providing a secured loan for a second system, with operations supported by technical partner HashForest. This move represents a strategic shift from planning to execution in the company's AI infrastructure business.
Value
$1.18M
Counterparty
Goodwill Labs Inc.
Term
60 months
“We are moving from strategy to execution. By placing our initial order and committing capital toward next-generation AI computing infrastructure, we are establishing the foundation for PDN Intelligence’s operations.”
Yiran Gu, Chief Executive Officer and Chief Financial Officer
“We believe demand for advanced computing capacity will continue to create opportunities across the AI ecosystem. Our approach is to begin with disciplined infrastructure deployment, establish operating capabilities and evaluate future expansion based on market demand, utilization and economics.”
Yiran Gu, Chief Executive Officer and Chief Financial Officer
Beeline Holdings provided a preliminary Q3 2026 update, expecting its highest revenue since 2021 and record margins driven by a strategic shift toward Non-QM lending. The company also announced the pending launch of a Home Equity Investment (HEI) product to diversify revenue away from interest-rate-sensitive traditional mortgages.
“Q3 is expected to demonstrate that the strategic changes we made beginning in April are working. We expect to deliver the second-highest revenue quarter in our history and our highest margins ever and our lowest adjusted EBITDA loss since 2021, while strengthening our cash position.”
Nick Liuzza, CEO and Co-Founder of Beeline
“Now we are preparing to add another significant growth opportunity with HEI. Homeowners have accumulated substantial equity, but higher interest rates can make accessing that equity through a traditional cash-out refinance or HELOC less attractive or, for some homeowners, unavailable.”
Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. provided a status update on its pending merger with Supernus Pharmaceuticals, Inc., specifically addressing supplemental disclosures to the joint proxy statement/prospectus. The update follows demand letters and complaints from Supernus stockholders alleging disclosure deficiencies, which the company believes are meritless but is addressing to avoid litigation risk. The special meetings for stockholders of both companies to vote on the merger are scheduled for October 15, 2026.